The medicine became the first new coronavirus drug to have the antiviral Favipiravir as an active ingredient. Avifavir is part of the official list of drugs that are used for COVID-19 prevention and treatment in Russia.
"During the first stage of clinical trials, it proved to be highly efficient," Russia's Health Ministry stated.
Sixty-five percent of the 40 patients who took Avifavir during clinical trials tested negative for COVID-19 on the fourth day of use. After ten days, 90 percent of the patients tested negative.